Healthcare Industry News: Optical Coherence Tomography
News Release - March 22, 2010
Tomophase Corporation Names Ralph S. Johnston President and Chief Operating OfficerBURLINGTON, Mass.--(HSMN NewsFeed)--Tomophase Corporation, a leading developer of non-invasive Optical Coherence Tomography (OCT) tissue imaging devices, announced today that Ralph S. Johnston has been appointed President and Chief Operating Officer of the company. The announcement was made by Dr. Peter Norris, CEO, Co-Founder and Chairman of the Board. Mr. Johnston brings over 25 years of experience in medical devices and pharmaceuticals to the business. He has held senior management positions in business development, strategic marketing and sales with venture-backed start-up enterprises and Fortune 500 companies Pfizer and Corning Medical.
Previously Mr. Johnston was involved in the start-up of Infusaid Corporation, a privately held medical device company that produced a totally implantable Class III drug infusion system. Pfizer acquired Infusaid and Mr. Johnston accepted an offer to remain with the company, ultimately serving as worldwide Vice President of Marketing and Sales of the Pfizer division. Mr. Johnston received an MBA from the Sawyer School of Management, Suffolk University, Boston, and earned a BA in Biology and Chemistry from Eastern Michigan University.
Dr. Norris states: “We are delighted to have Ralph join our team as we move forward with our development and commercialization plans, initially in Interventional Pulmonology. His previous experience in the U.S., Europe and Asia with sophisticated medical devices and his clinical relationships will be important assets for Tomophase.” Mr. Johnston noted: “The field of Interventional Pulmonology represents an important emerging opportunity for the diagnosis and treatment of lung cancer, asthma and other pulmonary diseases. Tomophase’s proprietary position in OCT imaging and therapeutic modalities is unique and exciting and I’m looking forward to contributing to move this technology to clinicians and patients.”
Tomophase Corporation is a privately held opto-medical device company with a proprietary position in real-time, high resolution, cross sectional tissue imaging using a variant of OCT. The company is engaged in the research and development of sophisticated fiber-optic catheters and imaging engines, used in conjunction with bronchoscopy, and initially focused on Interventional Pulmonology applications. . The OCTIS[tm] cross-sectional tissue imaging system is capable of interrogating structures 2-3 mm below the surface of the bronchi and lungs with the goal of early detection of malignancies and other lung diseases. Examples of our tissue imaging results are available at www.tomophase.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.